Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/6/2024 | $133.00 | Equal Weight | Barclays |
8/7/2023 | $100.00 → $142.00 | Neutral → Buy | UBS |
11/1/2022 | $97.00 → $72.00 | Buy → Hold | Deutsche Bank |
10/31/2022 | $117.00 → $74.00 | Buy → Neutral | UBS |
8/19/2022 | $106.00 → $117.00 | Buy | UBS |
6/21/2022 | $110.00 → $90.00 | Underperform | BofA Securities |
1/5/2022 | $114.00 → $125.00 | Hold | Truist Securities |
10/29/2021 | $113.00 → $111.00 | Sector Perform | RBC Capital |
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13D/A - DAVITA INC. (0000927066) (Subject)
DENVER, Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2024. "On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez, CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure." Financial and operating highlights for the quarter ended June 30, 2024: Consolidated revenues were $3.187 billion.Operating income was $506 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.59.Operating cas
DENVER, July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, August 6, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t
DENVER, May 2, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2024. "Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence," said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: Consolidated revenues were $3.071 billion.Operating income was $484 million and adjusted operating income was $463 million.Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
DENVER, Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2024. "On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez, CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure." Financial and operating highlights for the quarter ended June 30, 2024: Consolidated revenues were $3.187 billion.Operating income was $506 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.59.Operating cas
DENVER, July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, August 6, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00
UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously
Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously
TD Cowen analyst Gary Taylor maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $139 to $150.
DaVita Inc. (NYSE:DVA), a Colorado-based kidney dialysis provider, agreed to pay $34.5 million for allegedly paying kickbacks to a competitor for making referrals to DaVita Rx, a former subsidiary that provided pharmacy services for dialysis patients. DaVita also allegedly paid kickbacks to nephrologists and vascular access physicians to get patient referrals to DaVita's dialysis centers, the U.S. Department of Justice (DOJ) said on Thursday. The DOJ said DaVita violated the False Claims Act’s Anti-Kickback Statute, which prohibits providing any payments that are intended to induce referrals of patients or items or services covered by Medicare, Medicaid and other federally funded progr
- Bloomberg Citing DOJ
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),
Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care DENVER, May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide. "Nurses are such